MX2023000049A - Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. - Google Patents
Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.Info
- Publication number
- MX2023000049A MX2023000049A MX2023000049A MX2023000049A MX2023000049A MX 2023000049 A MX2023000049 A MX 2023000049A MX 2023000049 A MX2023000049 A MX 2023000049A MX 2023000049 A MX2023000049 A MX 2023000049A MX 2023000049 A MX2023000049 A MX 2023000049A
- Authority
- MX
- Mexico
- Prior art keywords
- cell therapy
- methods
- conditioning
- conditioning patients
- patients
- Prior art date
Links
- 238000002659 cell therapy Methods 0.000 title abstract 3
- 230000003750 conditioning effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960000390 fludarabine Drugs 0.000 abstract 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Abstract
La invención proporciona métodos para incrementar la eficacia de un tratamiento con linfocitos T en un paciente en necesidad de los mismos. La invención incluye un método para acondicionar un paciente antes de un tratamiento con linfocitos T, en donde el acondicionamiento involucra administrar una combinación de ciclofosfamida y fludarabina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562167750P | 2015-05-28 | 2015-05-28 | |
US201562262143P | 2015-12-02 | 2015-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000049A true MX2023000049A (es) | 2023-02-01 |
Family
ID=57393284
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015186A MX2017015186A (es) | 2015-05-28 | 2016-05-27 | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. |
MX2023000051A MX2023000051A (es) | 2015-05-28 | 2017-11-27 | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. |
MX2023000049A MX2023000049A (es) | 2015-05-28 | 2017-11-27 | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. |
MX2023000050A MX2023000050A (es) | 2015-05-28 | 2017-11-27 | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015186A MX2017015186A (es) | 2015-05-28 | 2016-05-27 | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. |
MX2023000051A MX2023000051A (es) | 2015-05-28 | 2017-11-27 | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000050A MX2023000050A (es) | 2015-05-28 | 2017-11-27 | Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t. |
Country Status (19)
Country | Link |
---|---|
US (4) | US9855298B2 (es) |
EP (2) | EP3851110A1 (es) |
JP (3) | JP7197979B2 (es) |
KR (3) | KR20220008388A (es) |
CN (2) | CN114344321A (es) |
AU (2) | AU2016268864B2 (es) |
BR (1) | BR112017025166A2 (es) |
CA (1) | CA2986798A1 (es) |
CL (1) | CL2017003006A1 (es) |
DO (1) | DOP2017000271A (es) |
EA (1) | EA201792649A1 (es) |
HK (2) | HK1246151A1 (es) |
IL (4) | IL295224A (es) |
MA (2) | MA43343A (es) |
MX (4) | MX2017015186A (es) |
PH (1) | PH12017502154A1 (es) |
SG (2) | SG10201913613SA (es) |
TW (2) | TW202319057A (es) |
WO (1) | WO2016191756A1 (es) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
SG11201703203RA (en) | 2014-10-20 | 2017-05-30 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
US9855298B2 (en) | 2015-05-28 | 2018-01-02 | Kite Pharma, Inc. | Methods of conditioning patients for T cell therapy |
PT3302507T (pt) | 2015-05-28 | 2023-05-23 | Kite Pharma Inc | Métodos de diagnóstico para terapia com células t |
PL3322425T3 (pl) | 2015-07-16 | 2023-10-09 | Yeda Research And Development Co., Ltd. | Zmodyfikowane genetycznie, skierowane przeciwko osobie trzeciej centralne limfocyty T pamięci i ich zastosowanie w immunoterapii |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
PT3436079T (pt) | 2016-04-01 | 2021-10-06 | Kite Pharma Inc | Recetores de antigénios quiméricos e de células t e métodos de uso |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
CA3023820A1 (en) | 2016-05-25 | 2017-11-30 | The Council Of The Queensland Institute Of Medical Research | Methods of immunotherapy |
US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
CN110392736A (zh) * | 2017-01-18 | 2019-10-29 | 耶达研究及发展有限公司 | 遗传修饰的反抑细胞及其在免疫治疗中的用途 |
SG11201906097VA (en) * | 2017-01-20 | 2019-08-27 | Atara Biotherapeutics Inc | Methods of treating multiple sclerosis using autologous t cells |
AU2018219226A1 (en) | 2017-02-07 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
CN110582287A (zh) | 2017-02-27 | 2019-12-17 | 朱诺治疗学股份有限公司 | 与在细胞疗法中给药有关的组合物、制品和方法 |
EP3589295A4 (en) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY |
US20180280437A1 (en) | 2017-03-13 | 2018-10-04 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
WO2018183927A1 (en) | 2017-04-01 | 2018-10-04 | Avm Biotechnology, Llc | Replacement of cytotoxic preconditioning before cellular immunotherapy |
EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
WO2018187332A1 (en) | 2017-04-03 | 2018-10-11 | Kite Pharma, Inc. | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
KR20200054160A (ko) * | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
KR20200055037A (ko) | 2017-09-19 | 2020-05-20 | 메사추세츠 인스티튜트 오브 테크놀로지 | 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도 |
CN109593711A (zh) * | 2017-10-02 | 2019-04-09 | 盖米达细胞有限公司 | 扩增自然杀手细胞部份的扩增方法及用途 |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
SG11202004003YA (en) | 2017-11-09 | 2020-05-28 | Sangamo Therapeutics Inc | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH |
CN111867680A (zh) | 2018-01-15 | 2020-10-30 | 辉瑞大药厂 | 组合施用嵌合抗原受体免疫疗法与4-1bb激动剂的方法 |
WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
WO2019170147A1 (zh) * | 2018-03-09 | 2019-09-12 | 科济生物医药(上海)有限公司 | 用于***的方法和组合物 |
EP3765094A4 (en) | 2018-03-15 | 2021-12-22 | KSQ Therapeutics, Inc. | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY |
SG11202005200XA (en) | 2018-03-22 | 2020-07-29 | Windmil Therapeutics Inc | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof |
WO2019191752A1 (en) * | 2018-03-30 | 2019-10-03 | Ohio State Innovation Foundation | Methods for pre-conditioning patients for t-cell therapy |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
KR20230093066A (ko) | 2018-06-01 | 2023-06-26 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
EP3810780A1 (en) | 2018-06-22 | 2021-04-28 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
AU2019311077A1 (en) * | 2018-07-23 | 2021-02-25 | Heidelberg Pharma Research Gmbh | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy |
AU2019310430A1 (en) * | 2018-07-23 | 2021-02-25 | Magenta Therapeutics, Inc. | Use of an anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy |
BR112021004383A2 (pt) | 2018-09-28 | 2021-08-03 | Massachusetts Institute Of Technology | proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
AU2020243703A1 (en) * | 2019-03-21 | 2021-11-11 | Gamida-Cell Ltd. | Expanded NK cell fractions for transplantation in combination therapy |
US11090336B2 (en) | 2019-03-27 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy |
EP3962490A4 (en) | 2019-05-03 | 2023-01-25 | Kite Pharma, Inc. | CHEMERA ANTIGEN RECEPTOR IMMUNOTHERAPY ADMINISTRATION METHODS |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
EP3990009A1 (en) | 2019-06-27 | 2022-05-04 | CRISPR Therapeutics AG | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
BR112022014501A2 (pt) * | 2020-01-24 | 2022-09-20 | Juno Therapeutics Inc | Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva |
WO2021191871A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
CN116528879A (zh) | 2020-10-28 | 2023-08-01 | 凯德药业股份有限公司 | 用于表征t细胞杂质的流式细胞术方法 |
US20220168407A1 (en) | 2020-11-05 | 2022-06-02 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
CN116917737A (zh) | 2021-01-10 | 2023-10-20 | 凯德药业股份有限公司 | T细胞疗法 |
CA3211006A1 (en) | 2021-02-20 | 2022-08-25 | Kite Pharma, Inc. | Gene markers for sellecting immunotherapies |
KR20230173179A (ko) | 2021-05-14 | 2023-12-26 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t세포 요법 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2023159001A1 (en) | 2022-02-15 | 2023-08-24 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
US20240002800A1 (en) | 2022-05-16 | 2024-01-04 | Mendus B.V. | Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy |
WO2024092227A1 (en) | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Factors for optimizing immunotherapy |
WO2024092152A1 (en) | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Improving efficacy and durable response of immunotherapy |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US20030031652A1 (en) | 2001-04-16 | 2003-02-13 | Bernhard Hering | Systems and methods for inducing mixed chimerism |
US7718196B2 (en) * | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
EP1545204B1 (en) * | 2002-09-06 | 2016-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
JP2013527753A (ja) | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
DK2649086T3 (en) * | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
CN103442768A (zh) | 2011-01-18 | 2013-12-11 | 宾夕法尼亚大学董事会 | 治疗癌的组合物和方法 |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
EP3144008B1 (en) | 2012-05-08 | 2018-01-17 | The John Hopkins University | Compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes |
US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
EP3010528B1 (en) | 2013-06-19 | 2019-09-11 | Massachusetts Institute of Technology | In vivo targeting of cells with ligand-conjugated particles |
IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and cancer drugs |
PT3302507T (pt) | 2015-05-28 | 2023-05-23 | Kite Pharma Inc | Métodos de diagnóstico para terapia com células t |
US9855298B2 (en) * | 2015-05-28 | 2018-01-02 | Kite Pharma, Inc. | Methods of conditioning patients for T cell therapy |
PT3436079T (pt) * | 2016-04-01 | 2021-10-06 | Kite Pharma Inc | Recetores de antigénios quiméricos e de células t e métodos de uso |
-
2016
- 2016-05-27 US US15/167,977 patent/US9855298B2/en active Active
- 2016-05-27 IL IL295224A patent/IL295224A/en unknown
- 2016-05-27 CN CN202210019434.0A patent/CN114344321A/zh active Pending
- 2016-05-27 MX MX2017015186A patent/MX2017015186A/es unknown
- 2016-05-27 BR BR112017025166A patent/BR112017025166A2/pt not_active Application Discontinuation
- 2016-05-27 CA CA2986798A patent/CA2986798A1/en active Pending
- 2016-05-27 SG SG10201913613SA patent/SG10201913613SA/en unknown
- 2016-05-27 WO PCT/US2016/034888 patent/WO2016191756A1/en active Application Filing
- 2016-05-27 CN CN201680030892.7A patent/CN107921066A/zh active Pending
- 2016-05-27 AU AU2016268864A patent/AU2016268864B2/en active Active
- 2016-05-27 KR KR1020227000444A patent/KR20220008388A/ko not_active Application Discontinuation
- 2016-05-27 EA EA201792649A patent/EA201792649A1/ru unknown
- 2016-05-27 JP JP2017561794A patent/JP7197979B2/ja active Active
- 2016-05-27 EP EP20204879.9A patent/EP3851110A1/en active Pending
- 2016-05-27 SG SG10201913604TA patent/SG10201913604TA/en unknown
- 2016-05-27 IL IL305621A patent/IL305621A/en unknown
- 2016-05-27 MA MA043343A patent/MA43343A/fr unknown
- 2016-05-27 KR KR1020177037017A patent/KR102349677B1/ko active IP Right Grant
- 2016-05-27 IL IL284173A patent/IL284173B2/en unknown
- 2016-05-27 KR KR1020237034999A patent/KR20230147769A/ko active Search and Examination
- 2016-05-27 MA MA055694A patent/MA55694A/fr unknown
- 2016-05-27 EP EP16800847.2A patent/EP3302508A4/en not_active Withdrawn
- 2016-05-27 IL IL255887A patent/IL255887B/en unknown
- 2016-05-30 TW TW111125144A patent/TW202319057A/zh unknown
- 2016-05-30 TW TW105116879A patent/TWI803447B/zh active
-
2017
- 2017-07-13 US US15/649,369 patent/US10322146B2/en active Active
- 2017-11-27 MX MX2023000051A patent/MX2023000051A/es unknown
- 2017-11-27 DO DO2017000271A patent/DOP2017000271A/es unknown
- 2017-11-27 MX MX2023000049A patent/MX2023000049A/es unknown
- 2017-11-27 MX MX2023000050A patent/MX2023000050A/es unknown
- 2017-11-27 PH PH12017502154A patent/PH12017502154A1/en unknown
- 2017-11-27 CL CL2017003006A patent/CL2017003006A1/es unknown
-
2018
- 2018-04-10 US US15/950,042 patent/US11491187B2/en active Active
- 2018-04-27 HK HK18105541.3A patent/HK1246151A1/zh unknown
- 2018-06-15 HK HK18107815.8A patent/HK1248141A1/zh unknown
-
2021
- 2021-07-02 JP JP2021110476A patent/JP7238030B2/ja active Active
-
2022
- 2022-08-31 AU AU2022224754A patent/AU2022224754A1/en active Pending
- 2022-09-27 US US17/954,070 patent/US20230158075A1/en active Pending
-
2023
- 2023-03-01 JP JP2023030596A patent/JP2023071823A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502154A1 (en) | Methods for conditioning patients for t cell therapy | |
DOP2017000272A (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
MX362725B (es) | Bacterias probioticas. | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
MA40535A (fr) | Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2015011905A (es) | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
TW201713323A (en) | Therapeutic compositions and methods of use thereof | |
MX2023007706A (es) | Nanoparticulas para su uso como vacuna terapeutica. | |
MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
TW202419092A (zh) | 為t細胞療法而調理患者的方法 | |
UA112357C2 (uk) | Спосіб індивідуальної цільової терапії дефіциту вітаміну d у пацієнтів із захворюваннями кістково-м'язової системи | |
UA97357U (en) | Method for laser therapy in the treatment of patients with exogenous depressive disorder with suicidal behavior | |
UA83680U (ru) | Способ комплексной реабилитации больных нейродермитом |